UCB Biopharma Sprl;President and Fellows of Harvard College
发明人:
Widenmaier, Scott B.,Roberts, Elisabeth Helen,Moore, Adrian Richard,Doyle, Carl Brendan,Adams, Ralph,Herve, Karine Jeannine Madeleine,Wales, Shauna Mhairi,Tyson, Kerry Louise,Hotamisligil, Gökh
申请号：
AU2016254215
公开号：
AU2016254215A1
申请日:
2016.04.29
申请国别(地区):
AU
年份:
2017
代理人:
摘要：
This invention is in the area of improved anti-aP2 antibodies and antigen binding agents, and compositions thereof, which target the lipid chaperone aP2/FABP4 (referred to as "aP2") for use in treating disorders such as diabetes, obesity, cardiovascular disease, fatty liver disease, and/or cancer, among others. In one aspect, improved treatments for aP2 mediated disorders are disclosed in which serum aP2 is targeted and the biological activity of aP2 is neutralized or modulated using low-binding affinity aP2 monoclonal antibodies, providing lower fasting blood glucose levels, improved systemic glucose metabolism, increased systemic insulin sensitivity, reduced fat mass, reduced liver steatosis, reduced cardiovascular disease and/or a reduced risk of developing cardiovascular disease.
